4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
NanoRepro AG (NN6) operates in the Diagnostics & Research industry and is headquartered in Marburg, Germany with about 22 employees. Its market capitalization is roughly €19 million. In the fiscal year ended 2024-12-31, NN6 reported €5M in revenue and (€2M) in net income.
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers products in the areas of family planning, preventive healthcare, intolerances, and infectious diseases.
Interactive charts & full statements → Open the NN6 valuation workbench →
| Income statement | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | €5M | €3M | €39M | €163M |
| Gross Profit | €3M | €2M | €12M | €57M |
| Operating Income (EBIT) | (€4M) | (€5M) | (€4M) | €39M |
| Net Income | (€2M) | (€5M) | (€4M) | €30M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Dividends Paid | — | (€2M) | (€6M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets | €39M | €42M | €50M | €79M |
| Total Liabilities | €1M | €1M | €2M | €22M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NN6 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms